Biogen (BIIB) has been in the focus with various engagements involving expansions, acquisitions and financial results. The neurology pipeline has been extended with the
Alcyone buyout, making the stock seen as undervalued. Both Jefferies and Canaccord Genuity initiate coverage on biogen with a
buy rating. A
higher dose of the SMA drug, Spinraza, had its application rejected by the FDA, though a minor setback, it sparked concerns. Despite these circumstances, Australian approval has uplifted Alzheimer's treatment and Leqembi, the first medicine that slows progression of early Alzheimer's has been authorized in the EU. Concurrently, Biogen has announced a
$2 billion manufacturing investment in North Carolina’s Research Triangle Park. Moreover, Biogen has an
First-Ever Oral Postpartum Depression Treatment, called ZURZUVAE, which gets EU Green Light for 14-Day Therapy. The
future outlook looks positive as Biogen's Q2 earnings have led the way, and following new pipeline milestones, the era of Biogen could change.
Biogen BIIB News Analytics from Wed, 02 Apr 2025 07:00:00 GMT to Sat, 27 Sep 2025 19:37:47 GMT -
Rating 8
- Innovation 7
- Information 7
- Rumor 2
